Analyst Price Targets — MRNS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 23, 2024 3:08 am | Jay Olson | Oppenheimer | $6.00 | $1.67 | StreetInsider | Oppenheimer Upgrades Marinus Pharmaceuticals (MRNS) to Outperform |
| April 16, 2024 3:06 am | Brian Skorney | Robert W. Baird | $2.00 | $1.30 | StreetInsider | Baird Downgrades Marinus Pharmaceuticals (MRNS) to Neutral, 'Phase 3 RAISE Study Doesn't Hit at Interim' |
| April 15, 2024 12:55 pm | Sector Perform | RBC Capital | $3.00 | $1.42 | TheFly | Marinus Pharmaceuticals downgraded to Sector Perform at RBC Capital |
| March 28, 2024 3:28 pm | Jay Olson | Oppenheimer | $9.00 | $9.04 | StreetInsider | Oppenheimer Reiterates Perform Rating on Marinus Pharmaceuticals (MRNS) |
No recent news available for MRNS.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MRNS.
U.S. House Trading
No House trades found for MRNS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.